A look at the P2 data presented at the American Academy of Dermatology Annual Meeting of Incyte's Opzelura in adult patients with hidradenitis suppurativa.

Executed on:Mar 27, 2024 4:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: DermacliniqueBoard-Certified Dermatologist in Private Practice and Medical Director of Dermatology at Premier Research, a CRO.
Treats 250 patients for Hidradenitis suppurativa
Clinical and research interest in systemic agents such as Biologics, JAK inhibitors, and Immunosuppressants with Phase I-IV clinical trial experience in dermatology

Interview Goal

On this call we will be discuss the potential of Incyte's JAK inhibitor, Opzelura, as a cream formulation for patient with HS based on the data presented at the AAD Annual Meeting in March.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.